Rs 100 crore R&D centre launched at Kandla SEZ

Rusan Pharma is a fully integrated global pharmaceutical company with interests in Research and Development, Manufacturing and Marketing of formulations, APIs and their intermediates

images234342

(Photo Courtesy: www.blogs.scientificamerican.com)

A state-of-the-art R&D centre ‘Navin Saxena Research & Technology', Clinical research organization - ‘Quest Care' and a specialised manufacturing unit for transdermal patches was launched yesterday at the Kandla Special Economic Zone (SEZ).

The facility, owned by parent company Rusan Pharma, is the only one in the country to manufacture Nicotine transdermal patches in India.

Rusan Pharma is a fully integrated global pharmaceutical company with interests in Research and Development, Manufacturing and Marketing of formulations, APIs and their intermediates.

Set up in alignment with the PM's ‘Make In India' initiative, it will go a long way in making the Kandla SEZ vibrant and investor-friendly.

The new establishment at Kandla houses three subsidiaries, namely the Navin Saxena Research and Technology (NSRT) Centre, Quest Care which is the company's clinical research organisation and Rusan's dedicated Transdermal Patch Facility.

 

Previous 1 3 4 5 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X